(Press-News.org) New research shows almost 90% of people in England would agree to genetic testing to get the most effective medication and reduce the risk of side effects
85% thought that the NHS should offer pharmacogenomic testing to people with multiple health conditions
58% of people thought that the NHS should offer this testing to everyone
91% wanted access to their own pharmacogenomic data, with many wanting this via the NHS app
Pharmacogenomics – an individual’s genetic response to medications – is an increasingly important strand of personalised healthcare but little is known about the public's views on it. Researchers at Queen Mary University of London, working with key partners, have carried out a first-of-its-kind public consultation to gather the public's views on pharmacogenetics.
How a person responds to medication is sometimes influenced by their genetic makeup. Some medications do not work as well for people with certain genetic variations, and in other cases can lead to serious side effects. Side effects account for one in 16 hospital admissions and have been estimated to cost the NHS £2.2 billion annually – demonstrating how important pharmacogenetic testing could be.
To gauge the public's attitudes on pharmacogenetics, a research team, led by Dr Emma Magavern at Queen Mary University of London in collaboration with the National Centre for Social Research (NatCen), surveyed a representative sample of UK adults. Dr Magavern’s team worked with the NHS England Network of Excellence for Pharmacogenomics and Medicines Optimisation and the Participant Panel at Genomics England. 2,719 responses were obtained (a response rate of 58%)
Key findings from the survey include:
Only half of participants knew that variations in DNA can predict either efficacy or side effects from a medication
People who were prescribed medication were almost twice as likely to want a PGx test
Most people (59%) reported experiencing either no benefit or a side effect from a medication.
Dr Emma Magavern, NIHR Clinical Academic Lecturer in Queen Mary’s Centre for Clinical Pharmacology and Precision Medicine who led the study, said: “This survey shows that many people in the UK feel that they have taken medication which has not been good for them, and most understand that people can respond differently to the same medication. There is widespread public support for personalising prescribing with genetic information and including this within NHS clinical care nationally, in partnership with patients and highlighting the key role of patient agency.”
Dr Rich Scott, Chief Executive Officer at Genomics England, said: “Pharmacogenomics holds enormous promise for improving health and helping to shift healthcare from reaction to prevention – and these results show it’s vital that the public are partners, not passengers, on this journey.
“This study shows that the public welcome using genetic testing to help make drug prescription safer and more effective, and that people want to be able to access their own data themselves. This is all vital information as we develop the digital infrastructure and evidence on how routine use of pharmacogenomics could become a routine part of healthcare in the coming years and have a real impact on patient care."
Dave McCormick, a member of the Participant Panel at Genomics England, said: “The Participant Panel were delighted to be involved in this important work. We are excited about the future for pharmacogenomics and encouraged that patients are being involved from the outset.”
This study was supported by NIHR Biomedical Research Centres at Barts and Manchester.
END
Almost 90% of people would agree to genetic testing to tailor medication use, survey finds
2025-02-20
ELSE PRESS RELEASES FROM THIS DATE:
Study: UTA research drives widespread economic impact
2025-02-19
University of Texas at Arlington research projects contributed $59 million to the national economy in 2024—an increase of 39% from 2023, according to a new report from the Institute for Research on Innovation and Science (IRIS).
UTA has invested heavily in research infrastructure, purchasing cutting-edge scientific equipment and technology, such as North Texas’ most advanced gene sequencer and a super-sensitive magnetic resonance imaging machine for the Clinical Imaging Research Center. The funds also support collaboration with other research organizations.
UTA worked through 1,144 unique ...
Promising results from first prenatal therapy for spinal muscular atrophy
2025-02-19
(MEMPHIS, Tenn. – February 19, 2025) Spinal muscular atrophy (SMA) is a progressive neurodegenerative disorder set in motion before birth. Scientists at St. Jude Children’s Research Hospital led the first in uterotreatment of SMA with the orally administered drug risdiplam. More than two years after the child was born, no identifiable features of SMA have been observed. This study demonstrates the feasibility of treating SMA prenatally and supports further investigation into the approach. The findings were published ...
Nitrogen fixation on marine particles is important in the global ocean
2025-02-19
How on Earth?
It has puzzled scientists for years whether and how bacteria, that live from dissolved organic matter in marine waters, can carry out N2 fixation. It was assumed that the high levels of oxygen combined with the low amount of dissolved organic matter in the marine water column would prevent the anaerobic and energy consuming N2 fixation.
Already in the 1980s it was suggested that aggregates, so-called “marine snow particles”, could possibly be suitable sites for N2fixation, ...
FDA approves vimseltinib for tenosynovial giant cell tumor (TGCT)
2025-02-19
The U.S. Food and Drug Administration (FDA) has approved vimseltinib (RomvimzaTM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue that lines the joints.
Sarcoma oncologist William Tap, MD, Chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center (MSK), led the international phase 3 MOTION trial that resulted in the drug’s approval. Vimseltinib is a type of targeted therapy called a kinase inhibitor and is taken as a pill.
“This approval is an exciting advance for ...
Columbia Climate School launches M.S. in Climate Finance
2025-02-19
The Columbia Climate School has announced the first master’s degree program in the United States for climate finance. In close collaboration with the Columbia Business School, this interdisciplinary degree will drive impactful solutions to the climate crisis through advanced financial tools and scientific knowledge. This is the third master’s program announced by the Climate School, in addition to an M.A. in Climate and Society and an M.S. in Climate degree.
“The world needs problem-solvers to address the global climate crisis,” said Alexis Abramson, dean of the Columbia Climate School. “Everyone ...
MD Anderson receives nearly $23 million in CPRIT funding for cancer research, faculty recruitment
2025-02-19
HOUSTON ― The University of Texas MD Anderson Cancer Center today was awarded nearly $23 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of 20 cancer research projects to advance new breakthroughs in discovery, translational, clinical and prevention science. In addition, CPRIT awarded $2 million for the recruitment of one first-time, tenure-track faculty member.
“We sincerely appreciate CPRIT’s continued funding of impactful cancer research that will help us achieve our mission to end cancer,” said ...
A new way to observe electrons in motion
2025-02-19
Electrons oscillate around the nucleus of an atom on extremely short timescales, typically completing a cycle in just a few hundred attoseconds (one attosecond is a quintillionth of a second). Because of their ultrafast motions, directly observing electron behavior in molecules has been challenging. Now researchers from UC San Diego’s Department of Chemistry and Biochemistry have suggested a new method to make visualizing electron motion a reality.
This new method describes an experimental concept called ultrafast vortex electron diffraction, which allows ...
Study reveals palm trees once thrived in subarctic Canada
2025-02-19
New London, Conn. — A new study by Connecticut College provides strong evidence that palm trees once thrived in subarctic Canada, reshaping scientific understanding of past Arctic climates.
Conn Professor Peter Siver’s research, published in the journal Annals of Botany, confirms that during the late early Eocene—approximately 48 million years ago—this region maintained warm temperatures year-round, even during months of winter darkness. The work was done in collaboration with colleagues from Canada and Poland.
Siver’s team identified fossilized phytoliths—microscopic ...
Is smoking tied to unexplained stroke in younger adults?
2025-02-19
MINNEAPOLIS — Smoking, particularly heavy smoking, is linked to some unexplained strokes in younger adults, mainly in male individuals and in people ages 45 to 49, according to a study published in the February 19, 2025, online issue of Neurology® Open Access, an official journal of the American Academy of Neurology.
A stroke with no known cause, called a cryptogenic stroke, is a type of ischemic stroke caused by a blockage of blood flow, but it is unclear what has caused the blockage. Symptoms include weakness, trouble speaking and vision problems. Strokes can be fatal. Most strokes occur after age 65.
“While smoking has long been linked to ischemic stroke, ...
Princeton Chemistry demonstrates high-performance Sodium-ion cathode towards new battery technology
2025-02-19
For decades, scientists have sought ways to counter our dependence on lithium-ion batteries. These traditional, rechargeable batteries energize today’s most ubiquitous consumer electronics – from laptops to cell phones to electric cars. But raw lithium is expensive and is often sourced through fragile geopolitical networks.
This month, Princeton University’s Dincă Group announces an exciting alternative that relies on an organic, high-energy cathode material to make sodium-ion batteries, advancing the likelihood that this technology will find commercialization with safe, cheaper, more sustainable components.
While scientists ...